2024 Innovation Awards
The recipients of the 2024 OHSU Innovation Awards exemplify what it means to be an innovator at OHSU. Through pioneering technologies and partnerships, these individuals and teams strive to translate new concepts into patient-centered solutions. This includes new cancer treatment strategies, anti-parasitic drug development and a wide-spanning collaboration with GE Healthcare.

We also celebrate OHSU members that achieved commercialization successes through patenting, licensing and new industry-sponsored research projects.

We hope that these stories inspire all OHSU members to see themselves as innovators and harness the resources offered by the OHSU Innovates network. By supporting intellectual property protection, collaboration agreements, providing startup guidance and entrepreneurial education, our ultimate goal is to empower all OHSU members to bring their ideas to life for societal impact.

Congratulations to all the awardees for their valuable contributions to the vibrant and growing OHSU innovation community.

Travis Cook, M.S., M.B.A., CLP
SENIOR DIRECTOR, TECHNOLOGY TRANSFER

Aditi Martin, Ph.D.
SENIOR DIRECTOR, COLLABORATIONS AND ENTREPRENEURSHIP
CREATORS OF LICENSED TECHNOLOGY

Connor Barth
Zachary Beattie
Luiz Bertassoni
Peter Campbell
Riccardo Carloni
Jessie May Cartier
Matthew Chang
Shawn Chavez
Yu-Jui (Roger) Chiu
Marissa Co
Lara Davis
Craig Dorrell
Brian Druker
Christopher Eide
Robert Eil
Lev Fedorov
Jack Ferracane
Mark Flory
Taisuke Furusho
Summer Gibbs
Markus Grompe
Nicholas Groves
Yukun Guo
Melanie Hakar
Jon Hennebold
Masahiro Horikawa
David Huang
Jennifer Jahncke
Yali Jia
Jeffrey Kaye
Dove Keith
Sancy Leachman
Jonathan Lee
Sanjay Malhotra
Andy Mendoza
Cristiane Miranda Franca
Antonio Montano
Terry Morgan
Hiroyuki Nakai
Brian O’Roak
Susan Ostmo
Justin Plaut
Srivathsan Ranganathan
Thomas Riley
Victoria Roberts
Rosalie Sears
Larry Sherman
Ov Slayden
Anthony Tahayeri
Dhanir Tailor
Eugene Tu
Jie Wang
Lei Wang
Richard Weleber
Kevin Wright
PRINCIPAL INVESTIGATORS OF NON-CLINICAL INDUSTRY SPONSORED RESEARCH

John Brigande
Brian Druker
Andrew Emili
Jack Ferracane
Brian Frank
Summer Gibbs
Cary Harding
Hiroshi Ishikawa
Aaron Janowsky
Yali Jia
Kelley Jordan
Bory Kea
Sancy Leachman
Jen-Jane Liu
Jeffrey Marbach
Lisa Marriott
Xiaolin Nan
Leonardo Pereira
Juan Piantino
Phil Raess
Rosalie Sears
Joseph Shatzel
Lawrence Sherman
Show-Ling Shyng
Daniel Streblow
Elie Traer
Brandon Wilder
David Wilson
Wassana Yantasee
<table>
<thead>
<tr>
<th>Inventors of Issued U.S. Patents</th>
<th>New Companies Based on OHSU Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avathamsa Athirasala</td>
<td>RegendoDent, Inc.</td>
</tr>
<tr>
<td>Eric Baker</td>
<td>Siloam Vision, Inc.</td>
</tr>
<tr>
<td>Tom Barbara</td>
<td>Unfold Therapeutics, Inc.</td>
</tr>
<tr>
<td>Luiz Bertassoni</td>
<td>Discovery Biotech, Inc.</td>
</tr>
<tr>
<td>Patrizia Caposio</td>
<td></td>
</tr>
<tr>
<td>Jack Ferracane</td>
<td></td>
</tr>
<tr>
<td>Klaus Frueh</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Gold</td>
<td></td>
</tr>
<tr>
<td>Yukun Guo</td>
<td></td>
</tr>
<tr>
<td>Matthew Hansen</td>
<td></td>
</tr>
<tr>
<td>Scott Hansen</td>
<td></td>
</tr>
<tr>
<td>Alec Hirsch</td>
<td></td>
</tr>
<tr>
<td>Wei Huang</td>
<td></td>
</tr>
<tr>
<td>Yali Jia</td>
<td></td>
</tr>
<tr>
<td>Ellen Langer</td>
<td></td>
</tr>
<tr>
<td>Xin Li</td>
<td></td>
</tr>
<tr>
<td>Nuria Marti-Gutierrez</td>
<td></td>
</tr>
<tr>
<td>Shannon McWeeney</td>
<td></td>
</tr>
<tr>
<td>Shoukhrat Mitalipov</td>
<td></td>
</tr>
</tbody>
</table>

Vishnu Mohan
Brendan Moloney
Hiroyuki Nakai
Edward Neuwelt
Carmem Pfeifer
Louis Picker
Jeffrey Pollock
Bill Rooney
Thomas Scanlan
Rosalie Sears
David Sheridan
Jessica Smith
Charles Springer
Daniel Streblow
Anthony Tahayeri
Jeffrey Tyner
Jeffrey Wu
Hua Xie
Wassana Yantasee
Alex Bartlett is a postdoctoral fellow working to develop new cancer therapies in the laboratory of Robert Eil, M.D. The innovative technology Bartlett helped develop could allow for a more targeted approach to cancer immunotherapies, which program the body’s own immune cells to target and kill cancer cells.

Bartlett’s commitment to advancing this promising therapy is evident in her active involvement with the OHSU Innovates network. Bartlett has worked to protect the intellectual property with Technology Transfer and secure funding for technology development through the OCTRI Biomedical Innovation Program. She has also engaged with the OHSU new ventures support, including the Entrepreneur-in-Residence program, and recently co-founded a new startup company, VertaBio.
The Career Innovation Excellence Award is presented to an OHSU member who, over the course of their career, has shown themselves to be an accomplished inventor and entrepreneur. They have demonstrated a true passion for innovation, been successful in engaging and cultivating partnerships with industry, and worked tirelessly to translate their discoveries into solutions for real-world problems and the benefit of society.

Mike Riscoe has dedicated his career to exploring innovative solutions for infectious diseases, particularly focusing on combating malaria, a tropical disease that claims roughly half a million lives annually worldwide. Throughout his tenure at OHSU, Riscoe has been a highly productive innovator, contributing to more than 35 invention disclosures and more than 70 patent applications. Many of these patents have since been licensed to industry partners for further drug development and validation.

What truly sets Riscoe apart is his collaborative spirit and the variety of successful partnerships he has formed during his career. He has had numerous academic collaborations, including one with Harvard University researchers for the development of mosquito nets coated with an antimalarial compound developed in the Riscoe lab. Riscoe also maintains productive collaborations with pharmaceutical companies to develop new drugs for the treatment and prevention of malaria. In addition, Riscoe has fostered an entrepreneurial environment in his laboratory, where numerous lab members play pivotal roles in industry collaborations and submit their own invention disclosures.
Robert Eil, M.D.
ASSISTANT PROFESSOR OF SURGERY, DIVISION OF SURGICAL ONCOLOGY, SCHOOL OF MEDICINE
ASSISTANT PROFESSOR OF CELL, DEVELOPMENTAL AND CANCER BIOLOGY, SCHOOL OF MEDICINE

Robert Eil is working to improve the safety of a highly effective therapy for blood cancers to extend it to other types of cancer. Chimeric antigen receptor engineered T-cells, or CAR T-cells, use the body's own immune cells to target and kill cancer cells. CAR T-cell therapies also have off-target effects, however, and have been thought to be too toxic to be used more broadly for other types of cancer.

Eil is working on a new approach that would allow CAR T-cell therapies to directly target the affected organ, thereby potentially improving the safety and applicability of this approach. The technology has enormous potential to improve cancer outcomes by making this effective therapy applicable to more patients. Eil's commitment to the project and his collaborative work with multiple OHSU Innovates teams have driven substantial progress in recent years, culminating in the development of a new OHSU startup VertaBio.
The Partnership Excellence Award is presented to an OHSU employee, or team of employees, who demonstrates an entrepreneurial spirit and works closely with the OHSU Innovates commercialization network to foster and encourage collaborations. They demonstrate a successful track-record of establishing and developing new partnerships to advance innovative research.

OHSU and GE HealthCare have developed a long-standing and productive collaboration spanning multiple areas to develop and implement new healthcare solutions. Joe Ness and Matthias Merkel are drivers of projects in this collaboration, including being instrumental in helping GE HealthCare rapidly implement real-time capacity tracking capability across Oregon through OHSU Mission Control. This tool provided critical occupancy information that enabled both large health systems and smaller rural hospitals across the state to maximize resources during the early days of the...
COVID pandemic. It has now transformed into the Oregon Capacity System operated by Apprise Health Insights in partnership with GE HealthCare and continues to serve as a critical capacity tool across the state.

The GE HealthCare collaboration also includes significant cardiovascular projects including cardiovascular imaging, interventional cardiology, and electrophysiology. These efforts, led by Joaquin Cigarroa, are focused on improving myocardial imaging, developing new approaches in structural cardiology, and using informatics and artificial intelligence in the treatment of arrhythmias. The collaboration is also developing novel concepts to improve how innovative cardiac procedures are taught and performed.
THANK YOU TO OUR SPONSORS

PLATINUM

GE HealthCare

SILVER

Lee & Hayes

Schwabe WILLIAMSON & WYATT®

Bronze

Kilpatrick Townsend

Stoel Rives LLP

Klarquist